BioCardia, Inc.
BCDA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000925741
In the last 90 days, BioCardia, Inc. insiders filed 10 open-market purchases and 0 sales; 21 institutions reported holding it in 13F filings for Q2 2026, worth $1.65M in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding BioCardia, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 16 | 18 | +2 |
| Shares | 304.3K | 427.1K | +122.7K (+40.3%) |
| Value | $593.2K | $551.9K | −$41.3K (−7.0%) |
New holders (5)
Institutions that held BioCardia, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Two Sigma Securities, LLC | 19,337 | $24.9K | 0.00% |
| Wealth Enhancement Advisory Services, LLC | 17,000 | $22.4K | 0.00% |
| XTX Topco Ltd | 16,177 | $20.9K | 0.00% |
| Citigroup Inc | 833 | $1.07K | 0.00% |
| Tower Research Capital LLC (TRC) | 97 | $125 | 0.00% |
Sold out (3)
Institutions that held BioCardia, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Cetera Investment Advisers | 20,275 | $39.5K |
| Raymond James Financial Inc | 1,838 | $3.58K |
| JPMorgan Chase & Co | 234 | $456 |